Samsung Biologics has launched a public tender offer to acquire 100% of PolyPeptide Group AG for CHF 44.31 per share in cash, valuing the Swiss-listed peptide contract manufacturer at approximately CHF 1.46 billion ($1.8 billion). The offer, announced on 20 July, represents a 40% premium to PolyPeptide's undisturbed share price of CHF 31.65 recorded on 10 April — the last trading day before market speculation about a potential deal emerged.
PolyPeptide's board of directors has unanimously recommended that shareholders accept the bid. Chairman Peter Wilden said the board had conducted "a comprehensive review of strategic options" and concluded that Samsung's offer is "compelling," delivering "an attractive cash price and immediate, certain value" for shareholders. The company simultaneously disclosed a "marked acceleration in growth and profitability" in the first half of 2026, suggesting the deal captures the business at an inflection point.
The strategic imperative for Samsung Biologics is rooted in the explosive growth of peptide-based therapeutics, particularly GLP-1 analogs used in obesity and diabetes treatments. The Korean company has built its global position as one of the largest biologics CDMOs on the back of monoclonal antibody manufacturing, but expanding into peptide active pharmaceutical ingredients through PolyPeptide gives it a new modality in what has become one of the pharmaceutical industry's fastest-growing segments. The deal adds PolyPeptide's manufacturing and development network across Sweden, Belgium, France, the United States, and India — facilities that have produced more than 1,000 therapeutic peptides since the company spun off from Ferring in 1996.
For the broader CDMO industry, the transaction underscores a consolidation dynamic that has been accelerating. Large, diversified contract manufacturers are acquiring specialized players to build multi-modality platforms capable of serving pharmaceutical clients across biologics, peptides, antibody-drug conjugates, and oligonucleotides. Samsung's move places additional competitive pressure on rivals such as Lonza, WuXi, and Catalent, all of which are positioning for the same shift. PolyPeptide's delisting, should the deal close, will further reduce the number of independent, pure-play peptide CDMOs available to investors and pharmaceutical buyers alike.
The offer is subject to a minimum acceptance threshold of 66⅔% of PolyPeptide's fully diluted share capital and customary regulatory approvals across relevant jurisdictions. Samsung Biologics has stated its intention to pursue a squeeze-out of remaining minority shareholders and delist PolyPeptide from SIX Swiss Exchange upon completion. The transaction is expected to close toward the end of 2026.
Board members evaluating the pharmaceutical supply chain should note the signal this deal sends about where value is migrating. The companies manufacturing the active ingredients for GLP-1 and adjacent peptide therapies are becoming strategic assets in their own right. With Samsung prepared to pay a 40% premium for that capability, the pricing of peptide CDMO capacity has been reset. The question for boards of companies dependent on outsourced peptide manufacturing is whether the remaining independent suppliers will face similar acquisition interest — and what that means for long-term supply security and pricing.
Source: CNBC
The Boardroom Report · Published by Tetmo Publishing
Subscribe · Group pricing available